What do we know about IDH1/2 mutations so far, and how do we use it?
about
New perspectives in glioblastoma antiangiogenic therapyOligodendroglioma: pathology, molecular mechanisms and markersEpidemiologic and molecular prognostic review of glioblastomaPredicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapyMassive dissemination from spinal cord gangliogliomas negative for BRAF V600E: report of two rare adult cases.Isocitrate dehydrogenase mutations in gliomasCD151-α3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion.IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomasAutophagy and oxidative stress in gliomas with IDH1 mutationsIDH1/2 mutation detection in gliomas.Isocitrate dehydrogenase 1 and 2 mutations in gliomas.Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers.Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.Mutant IDH1 and thrombosis in gliomas.Characterization of gliomas: from morphology to molecules.Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.Molecular Markers in the Diagnosis and Treatment of Cancer.Mutant IDH1 and seizures in patients with glioma.Neurological update: gliomas and other primary brain tumours in adults.Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.Erratum to: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas.Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report.D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation.Commentary on "Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813".Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas.Association between mutations and brain glioma grade
P2860
Q26746028-1AD1C3EE-C1A7-458B-8C4C-9A6E7BA576C0Q27002448-6C098D50-0D3A-473C-B0B9-8CE31C1001BBQ28395302-C9CFCB38-4740-429C-9B8C-003B4F873535Q34359670-180434EA-A082-49AA-8682-84DDE508ADB7Q34364774-4B632BDA-FFFC-49CB-BB07-B94EB645C08DQ35572487-23209083-2D93-4D35-9C30-E7071002FDE5Q36192363-A8FB8770-5F07-4679-AF2F-C8977CE608EEQ36367409-C8814B14-488E-418F-8E6F-B356AE138BA3Q36557409-D4537F28-4396-498D-A705-123A09850C0FQ36557547-2274A267-2CEC-4B38-8351-72AFBA380E15Q36557573-623DD474-16BB-42DB-936A-813C4F4B7393Q36618268-1066D06D-379D-4736-BFC8-4089B2F5E54CQ37403150-8ACAD8BC-E2AD-4F86-8A02-3E0A2469C95FQ37625457-F9FA21D4-4021-47DA-A191-87CA13667B91Q38227739-3E1D82E2-7651-4B76-A334-425369633895Q38235572-16CA05E4-7AE9-488B-BE31-15718CB93536Q38480437-C980B671-FDF9-46B3-B8EC-6181EAFEC0D6Q38658533-6008F6A9-32D7-4939-9431-E735D00016D1Q38670567-6F202ED3-AC33-4D36-BEED-EF91B880777EQ38890122-556F83FD-544A-404C-94F8-78366E7E24C6Q39355644-C7A2A58E-F0EB-410D-89B3-BCFC5303A495Q39412967-B1582F18-9D82-4F93-8929-BFB448EDD939Q40822804-D0FAFBC4-3D54-4533-B0E6-901182999247Q41468666-67107172-FAFE-4F9F-AAD9-0C973E9BB186Q42652909-C8F257A6-7E8C-4F21-BD2A-C02AD718C906Q42712893-222E67D3-5A56-403B-8CE8-C51210B0C89FQ46022640-152EE3A9-B825-4723-9C9B-523619DB6C69Q47989137-52AAF16F-8C2C-4836-9BE5-A2876558E8C1Q48149731-8B4DF0A1-3B17-4ACF-A356-95DFD38D2EA1Q48308655-8D1DB1D5-4322-4EE6-826C-54FDABD0482DQ48822182-353228D2-BF57-4119-920A-B52A22C981D0Q53433176-D958F0EC-9F7F-4E84-85E8-BFEBA47DEAAAQ55058949-B409DF1F-ED32-4919-BD50-4563E0E03907Q55457298-68086F6B-D439-4F60-A65A-4A6C95AE2BE1Q55460981-96F9158E-837B-429D-8159-4F8ACB261173Q58767669-A3B835E6-C828-4C59-A69B-8A64AF22FB41
P2860
What do we know about IDH1/2 mutations so far, and how do we use it?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
What do we know about IDH1/2 mutations so far, and how do we use it?
@en
type
label
What do we know about IDH1/2 mutations so far, and how do we use it?
@en
prefLabel
What do we know about IDH1/2 mutations so far, and how do we use it?
@en
P2860
P1476
What do we know about IDH1/2 mutations so far, and how do we use it?
@en
P2093
Craig Horbinski
P2860
P2888
P304
P356
10.1007/S00401-013-1106-9
P577
2013-03-20T00:00:00Z